Off-label-brug af psykofarmaka til børn og unge i Danmark

TY - JOUR

T1 - Off-label-brug af psykofarmaka til børn og unge i Danmark

AU - Pagsberg, Anne Katrine

AU - Thomsen, Per Hove

PY - 2017

Y1 - 2017

N2 - Despite regulatory initiatives, psychopharmacological treatment of adolescents is challenged by missing trial data on efficacy and safety. In Denmark, an estimated mean off-label prescription rate of 30-40% in clinical child- and adolescent mental health services has been found in recent studies. The lowest rates were found for drugs treating ADHD (2-3%), and the highest for antipsychotics (96%) and melatonin (100%). The use of melatonin is growing, while the use of other psychopharmacological drugs appears to be stabilizing or decreasing, in spite of an increased number of adolescents treated in Danish mental health services.

AB - Despite regulatory initiatives, psychopharmacological treatment of adolescents is challenged by missing trial data on efficacy and safety. In Denmark, an estimated mean off-label prescription rate of 30-40% in clinical child- and adolescent mental health services has been found in recent studies. The lowest rates were found for drugs treating ADHD (2-3%), and the highest for antipsychotics (96%) and melatonin (100%). The use of melatonin is growing, while the use of other psychopharmacological drugs appears to be stabilizing or decreasing, in spite of an increased number of adolescents treated in Danish mental health services.

M3 - Tidsskriftartikel

C2 - 28874238

SN - 0041-5782

VL - 179

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

M1 - V05170355

ER -